BRPI1012170A2 - formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. - Google Patents
formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.Info
- Publication number
- BRPI1012170A2 BRPI1012170A2 BRPI1012170A BRPI1012170A BRPI1012170A2 BR PI1012170 A2 BRPI1012170 A2 BR PI1012170A2 BR PI1012170 A BRPI1012170 A BR PI1012170A BR PI1012170 A BRPI1012170 A BR PI1012170A BR PI1012170 A2 BRPI1012170 A2 BR PI1012170A2
- Authority
- BR
- Brazil
- Prior art keywords
- ingested
- sublingual
- formulation
- reducing
- achieve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009902280A AU2009902280A0 (en) | 2009-05-20 | Improved therapeutic formulations | |
PCT/AU2010/000594 WO2010144943A1 (en) | 2009-05-20 | 2010-05-20 | Buccal and/or sublingual therapeutic formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1012170A2 true BRPI1012170A2 (pt) | 2016-03-29 |
Family
ID=43355588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1012170A BRPI1012170A2 (pt) | 2009-05-20 | 2010-05-20 | formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20120058962A1 (pt) |
EP (1) | EP2437730A4 (pt) |
JP (1) | JP2012527406A (pt) |
CN (1) | CN102612363A (pt) |
AU (3) | AU2010262738A1 (pt) |
BR (1) | BRPI1012170A2 (pt) |
CA (1) | CA2761538A1 (pt) |
MX (1) | MX2011012078A (pt) |
WO (1) | WO2010144943A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9254294B2 (en) | 2003-02-24 | 2016-02-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
US8568776B2 (en) | 2011-02-11 | 2013-10-29 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
CA3208225A1 (en) | 2012-01-16 | 2013-07-25 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatitic diseases and disorders |
CN102525979B (zh) * | 2012-02-07 | 2013-03-27 | 海南卫康制药(潜山)有限公司 | 一种小儿布洛芬组合物 |
CN110227152A (zh) * | 2012-04-23 | 2019-09-13 | 巴拉特生物技术国际有限公司 | 轮状病毒疫苗组合物及其制备方法 |
JP5877778B2 (ja) * | 2012-05-28 | 2016-03-08 | 株式会社ホットアルバム炭酸泉タブレット | 錠剤の製造方法及び錠剤 |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2014047588A1 (en) | 2012-09-21 | 2014-03-27 | Elizabeth Mckenna | Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof |
NZ628963A (en) | 2012-11-13 | 2017-02-24 | Gordagen Pharmaceuticals Pty Ltd | Transmucosal delivery of tocotrienol |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2881992C (en) | 2013-04-23 | 2016-11-22 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
WO2014195032A1 (en) | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
JP7077589B2 (ja) * | 2016-11-29 | 2022-05-31 | 大正製薬株式会社 | 固形製剤 |
WO2019246074A1 (en) * | 2018-06-18 | 2019-12-26 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
WO2021019278A1 (en) * | 2019-07-28 | 2021-02-04 | Debasish Banerjee | Enhancing drug activity through accentuated buccal/sublingual administration |
EP4061331A1 (en) * | 2019-11-22 | 2022-09-28 | Wockhardt Limited | Oral film composition comprising levothyroxine |
WO2022234593A1 (en) * | 2021-05-02 | 2022-11-10 | Zenvision Pharma Llp | Sublingual compositions comprising nintedanib or salt thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6064915A (ja) * | 1983-09-20 | 1985-04-13 | Grelan Pharmaceut Co Ltd | 軟質な口腔製剤 |
GB8426152D0 (en) * | 1984-10-16 | 1984-11-21 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
US5244668A (en) * | 1988-10-14 | 1993-09-14 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
DE3927723A1 (de) * | 1989-01-26 | 1990-08-02 | Ulrich Prof Dr Speck | N - acetylglucosamin zur buccalen anwendung |
FR2718020B1 (fr) * | 1994-04-01 | 1996-05-31 | Biotec Centre Sa | Composition galénique mucoadhésive hétérofonctionnelle. |
CZ297382B6 (cs) * | 1995-03-02 | 2006-11-15 | R.P. Scherer Limited | Rychle se dispergující orální pevná dávková formafarmaceutického prostredku pro lécení Parkinsonovy nemoci |
TW442287B (en) * | 1995-06-13 | 2001-06-23 | American Home Produits Corp | Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac) |
WO1997038679A2 (en) * | 1996-04-16 | 1997-10-23 | Novartis Consumer Health S.A. | Fast disintegrating oral dosage form |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
DK1411899T3 (da) * | 2001-08-01 | 2009-06-02 | Novartis Ag | Smagsmaskerende sammensætning |
US6884790B2 (en) * | 2002-09-09 | 2005-04-26 | Josef Pitha | Verifiable absorption drug delivery form based on cyclodextrins |
SE0300831D0 (sv) * | 2003-03-26 | 2003-03-26 | Pharmacia Ab | New formulations and use therof |
ITRM20030288A1 (it) * | 2003-06-10 | 2004-12-11 | Valerio Cioli | Somministrazione sublinguale di antinfiammatori non steroidei (fans) |
GB0320854D0 (en) * | 2003-09-05 | 2003-10-08 | Arrow No 7 Ltd | Buccal drug delivery |
GB0423800D0 (en) * | 2004-10-27 | 2004-12-01 | Orexo Ab | New pharmaceutical formulations |
WO2006101536A1 (en) * | 2004-11-04 | 2006-09-28 | Akina, Inc. | Fast-melting tablets having taste-masking and sustained release properties |
JP5256425B2 (ja) * | 2005-04-08 | 2013-08-07 | リングアル コンセグナ ピーティーワイ エルティーディー | 口腔送達システム |
EP1898879A1 (en) * | 2005-06-23 | 2008-03-19 | Schering Corporation | Rapidly absorbing oral formulations of pde5 inhibitors |
MX2008001520A (es) * | 2005-08-01 | 2008-04-07 | Teva Pharma | Composiciones de tizanidina y metodos de tratamiento usando las composiciones. |
US8007783B2 (en) * | 2006-08-22 | 2011-08-30 | Carl Miller | Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine |
-
2010
- 2010-05-20 WO PCT/AU2010/000594 patent/WO2010144943A1/en active Application Filing
- 2010-05-20 BR BRPI1012170A patent/BRPI1012170A2/pt not_active Application Discontinuation
- 2010-05-20 JP JP2012511094A patent/JP2012527406A/ja active Pending
- 2010-05-20 CN CN2011800021286A patent/CN102612363A/zh active Pending
- 2010-05-20 EP EP10788488.4A patent/EP2437730A4/en not_active Withdrawn
- 2010-05-20 MX MX2011012078A patent/MX2011012078A/es not_active Application Discontinuation
- 2010-05-20 AU AU2010262738A patent/AU2010262738A1/en not_active Abandoned
- 2010-05-20 US US13/256,844 patent/US20120058962A1/en not_active Abandoned
- 2010-05-20 CA CA2761538A patent/CA2761538A1/en not_active Abandoned
-
2016
- 2016-10-06 AU AU2016238901A patent/AU2016238901A1/en not_active Abandoned
-
2018
- 2018-08-15 AU AU2018217251A patent/AU2018217251A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2437730A1 (en) | 2012-04-11 |
US20120058962A1 (en) | 2012-03-08 |
CA2761538A1 (en) | 2010-12-23 |
EP2437730A4 (en) | 2014-02-26 |
AU2016238901A1 (en) | 2016-10-20 |
AU2018217251A1 (en) | 2018-08-30 |
WO2010144943A1 (en) | 2010-12-23 |
AU2010262738A1 (en) | 2011-10-13 |
JP2012527406A (ja) | 2012-11-08 |
CN102612363A (zh) | 2012-07-25 |
MX2011012078A (es) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1012170A2 (pt) | formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. | |
BRPI1013503A2 (pt) | formulação de iniciador não cromado que inibe corrosão, e, estrutura | |
BR112013030599A2 (pt) | núcleo absorvente para artigos absorventes descartáveis | |
BR112013013402A2 (pt) | combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos | |
BR112012019529A2 (pt) | inibidores de d-nitrosoglutationa redutase | |
BR112012031500A8 (pt) | Composições sólidas | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BR112013010078A2 (pt) | sistema de prevenção de ferida de pressão e método para evitar o desenvolvimento de feridas de pressão de um indivíduo | |
BRPI0813866A2 (pt) | Vacinas contra influenza com baixo teor de aditivos | |
BR112012027279A2 (pt) | composições de emulsão farmacêutica com baixo teor de óleo que compreendem progestogênio | |
WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
BR112013016897A2 (pt) | composição oftálmica aquosa | |
CL2012002422A1 (es) | Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral. | |
BRPI0917625A2 (pt) | substratos que fornecem liberações multiplas de agentes ativos | |
BRPI1007619A2 (pt) | "sistema para prevenção de quedas adequado para ser usado por um usuário e métoddo de operação de um sistema para prevenção de quedas que seja usado pelo usuário" | |
BR112012032087A2 (pt) | composto, medicamento, e, uso de um composto | |
BR112012028719A2 (pt) | composição de tratamento de superfície dura, método para fornecer um efeito antimicrobiano a uma superfície dura e uso de uma combinação | |
BR112012015084A2 (pt) | composição farmacêutica de liberação lenta de iloperidone | |
WO2012154122A3 (en) | A topical formulation for treatment of hyperkeratotic skin | |
BR112012019351A2 (pt) | composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica. | |
CL2014001157A1 (es) | Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato. | |
BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
EA201290373A1 (ru) | Синергическая противовирусная композиция и ее применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |